Anthem Biosciences Manufacturing Expansion Plan : Anthem Biosciences’ IPO (₹540-570/share) funds expansion of its peptide & fermentation API facilities, leveraging <20% China dependence and 37% EBITDA margins.
Anthem Biosciences Manufacturing Expansion Plan : Key Highlights
✅ IPO Details:
- Price Band: ₹540-570/share
- Dates: July 14-16 (Public), July 11 (Anchor)
- Listing: Expected July 21
✅ Manufacturing Expansion: - Unit 3 (Peptides/Fermentation): Operational (₹600cr investment)
- Unit 4 (30-acre facility): Under construction (2-year timeline)
✅ Financial Strength: - 37% EBITDA margins
- 80% export revenue (US/EU/China)
- 16 late-stage projects in pipeline
Strategic Positioning in Global Pharma Supply Chains
Competitive Advantages
| Factor | Anthem’s Edge |
|---|---|
| China Dependence | <20% raw material sourcing vs industry’s 60-70% |
| Regulatory Compliance | Zero-observation USFDA audits |
| Product Mix | High-margin fermentation APIs, peptides, probiotics |
| Tech Integration | Cloud-based plant monitoring systems |
Ajay Bhardwaj, CEO:
“Our decade-long supply chain de-risking delivers reliability that global innovators value, especially post-COVID.”
Facility-wise Capabilities
Operational Units
- Unit 1 & 2: FDA-approved for advanced intermediates
- Unit 3: Dedicated to peptides & fermentation (probiotics/enzymes)
Upcoming Unit 4 (2026)
- 30-acre campus (Larger than Units 1-3 combined)
- Focus: Commercial-scale fermentation APIs
- Automation: Industry 4.0 controls
Market Opportunities
Global Demand Drivers
✔ Probiotics market: $85B by 2027 (12% CAGR)
✔ Therapeutic peptides: $50B+ opportunity
✔ “China+1” sourcing shifts in pharma
Client Segmentation
- Big Pharma: 50% revenue
- Emerging Biotech: 20%
- Indian Market: 20% (growing absolute value)
IPO Utilization & Growth Plan
Capital Allocation
- Debt reduction (Current gross block: ₹1,300cr+)
- Unit 4 completion (₹300cr CWIP)
- R&D scale-up for 16 pipeline projects
Investor Appeal
✔ Niche CRDMO model vs generic API players
✔ Regulatory-compliant operations
✔ Wellness segment expansion
Sources: Company RHP, Pharma Market Reports
Data as of July 2024 IPO filing
